Literature DB >> 16006605

Pathology of end-stage remodeling in a family of cats with hypertrophic cardiomyopathy.

M F Cesta1, C J Baty, B W Keene, I W Smoak, D E Malarkey.   

Abstract

End-stage hypertrophic cardiomyopathy (ES-HCM), affecting 5-10% of human hypertrophic cardiomyopathy (HCM) patients, is characterized by relative thinning of the ventricular walls and septum with dilation of the ventricular lumen, decreased fractional shortening, and progression to heart failure. C. J. Baty and others recently documented similar progressive changes to ES-HCM in a family of four cats through serial echocardiograms. At the time of heart failure, these cats exhibited changes similar to those exhibited by human ES-HCM patients. Our objectives were to describe the pathologic alterations associated with ES-HCM and investigate the pathogenesis in three of the four cats. Grossly, there was left atrial dilation with relative thinning of the interventricular septum (IVS) and left ventricular free wall (LVFW). The left atrium contained large thrombi in two of the three cats, and all three cats died following thromboembolization of the aortic bifurcation. Histologically, all three cats had subendocardial and myocardial fibrosis, predominantly of the IVS and LVFW, and one cat had acute, multifocal, myocardial infarcts with mononuclear inflammatory cell infiltrates. The pathogenesis of ES-HCM is uncertain, but theories implicate occlusion of the coronary blood flow by thickening of the coronary vessels, coronary vascular thromboembolism or coronary vessel spasm, apoptosis of myocytes, and myocardial hypertrophy beyond the ability of the vasculature to supply blood. Apoptosis assays did not reveal any apoptotic myocytes. Considering the hypercoagulative state of these cats, coronary vascular thromboembolism could be a major contributing factor. We cannot exclude apoptosis or coronary vessel spasm on the basis of the data presented.

Entities:  

Mesh:

Year:  2005        PMID: 16006605     DOI: 10.1354/vp.42-4-458

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  9 in total

1.  End-stage hypertrophic cardiomyopathy in a cat.

Authors:  Andrew J M White
Journal:  Can Vet J       Date:  2015-05       Impact factor: 1.008

2.  Pharmacodynamic effects of ivabradine, a negative chronotropic agent, in healthy cats.

Authors:  Richard E Cober; Karsten E Schober; Tony C A Buffington; Xiaobai Li; Sabine C Riesen; John D Bonagura
Journal:  J Vet Cardiol       Date:  2011-10-24       Impact factor: 1.701

3.  Investigations into the Sarcomeric Protein and Ca2+-Regulation Abnormalities Underlying Hypertrophic Cardiomyopathy in Cats (Felix catus).

Authors:  Andrew E Messer; Jasmine Chan; Alex Daley; O'Neal Copeland; Steven B Marston; David J Connolly
Journal:  Front Physiol       Date:  2017-06-08       Impact factor: 4.566

4.  Echocardiographic Assessment of Right Ventricular Size and Function in Cats With Hypertrophic Cardiomyopathy.

Authors:  L C Visser; C Q Sloan; J A Stern
Journal:  J Vet Intern Med       Date:  2017-03-13       Impact factor: 3.333

5.  International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study.

Authors:  Philip R Fox; Bruce W Keene; Kenneth Lamb; Karsten A Schober; Valerie Chetboul; Virginia Luis Fuentes; Gerhard Wess; Jessie Rose Payne; Daniel F Hogan; Alison Motsinger-Reif; Jens Häggström; Emilie Trehiou-Sechi; Deborah M Fine-Ferreira; Reid K Nakamura; Pamela M Lee; Manreet K Singh; Wendy A Ware; Jonathan A Abbott; Geoffrey Culshaw; Sabine Riesen; Michele Borgarelli; Michael B Lesser; Nicole Van Israël; Etienne Côté; John E Rush; Barret Bulmer; Roberto A Santilli; Andrea C Vollmar; Maribeth J Bossbaly; Nadine Quick; Claudio Bussadori; Janice M Bright; Amara H Estrada; Dan G Ohad; Maria Josefa Fernández-Del Palacio; Jenifer Lunney Brayley; Denise S Schwartz; Christina M Bové; Sonya G Gordon; Seung Woo Jung; Paola Brambilla; N Sydney Moïse; Christopher D Stauthammer; Rebecca L Stepien; Cecilia Quintavalla; Christophe Amberger; Ferenc Manczur; Yong-Wei Hung; Remo Lobetti; Marie De Swarte; Alice Tamborini; Carmel T Mooney; Mark A Oyama; Andrey Komolov; Yoko Fujii; Romain Pariaut; Masami Uechi; Victoria Yukie Tachika Ohara
Journal:  J Vet Intern Med       Date:  2018-04-16       Impact factor: 3.333

6.  Cardiac troponin I and T as prognostic markers in cats with hypertrophic cardiomyopathy.

Authors:  R Langhorn; I Tarnow; J L Willesen; M Kjelgaard-Hansen; I M Skovgaard; J Koch
Journal:  J Vet Intern Med       Date:  2014-07-23       Impact factor: 3.333

7.  Association of diet with left ventricular wall thickness, troponin I and IGF-1 in cats with subclinical hypertrophic cardiomyopathy.

Authors:  Ingrid van Hoek; Hannah Hodgkiss-Geere; Elizabeth F Bode; Julie Hamilton-Elliott; Paul Mõtsküla; Valentina Palermo; Yolanda Martinez Pereira; Geoff J Culshaw; Jeremy Laxalde; Joanna Dukes-McEwan
Journal:  J Vet Intern Med       Date:  2020-10-29       Impact factor: 3.333

8.  The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy.

Authors:  Mark D Kittleson; Etienne Côté
Journal:  J Feline Med Surg       Date:  2021-11       Impact factor: 2.015

9.  Findings suggestive of coronary microvascular dysfunction in cats with myocardial ischemia.

Authors:  Guillermo Belerenian; Pablo Alejandro Donati; Cristian Daniel Rodriguez; Victor Castillo; Juan Manuel Guevara; Claudia Pucheta; Sergio Ferraris; Roberto Walter Israel Olivares
Journal:  Open Vet J       Date:  2021-09-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.